Artivabio
San Diego, US · 5 known investors
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for conditions such as rheumatoid arthritis and Sjögren's disease.
BiotechHealthtech
Investors · 5
Frequently asked questions
- What does Artivabio do?
- Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for conditions such as rheumatoid arthritis and Sjögren's disease.
- Who are Artivabio's investors?
- Artivabio's investors include 5AM Ventures, EcoR1 Capital, RA Capital, venBio Partners, venBio Global Strategic.
- Where is Artivabio headquartered?
- Artivabio is headquartered in San Diego, US.